BioTuesdays
Markets

SVB Leerink starts Mereo BioPharma at OP; PT $8

SVB Leerink initiated coverage of Mereo BioPharma Group PLC (NASDAQ:MREO) with an “outperform” rating and price target of $8. The stock closed at $2.89 on Oct. 9. “We believe this rare disease-focused biopharma company...

October 10, 2019
Vericel Logo
Markets

HCW starts Vericel at buy; PT $19

H.C. Wainwright initiated coverage of Vericel (NASDAQ:VCELL) with a “buy” rating and $19 price target. The stock closed at $13.82 on Oct. 8. Vericel, a commercial wound care company, markets two innovative tissue...

October 9, 2019
Zosano Logo
Executive Moves

Zosano Pharma names Steven Lo as CEO

Steven Lo Zosano Pharma (NASDAQ:ZSAN) has appointed Steven Lo as president, CEO and a director, effective Oct. 21. Mr. Lo is departing from his role as CCO at Puma Biotechnology (NASDAQ:PUMA), effective Oct. 18, where...

October 8, 2019
Developments

FDA approves Pfenex osteoporosis drug

The FDA approved Pfenex’s (NASDAQ:PFNX) PF708 for the treatment of osteoporosis in patients at high risk of fracture. “The FDA’s approval of PF708 marks a major milestone in Pfenex’s history as our first approved...

October 8, 2019
Satsuma Pharmaceuticals
Markets

SVB Leerink starts Satsuma Pharma at OP; PT $20

SVB Leerink launched coverage of Satsuma Pharmaceuticals (NASDAQ:STSA) with an “outperform” rating and $20 price target. The stock closed at $10.70 on Oct. 7. STS101, Satsuma’s lead asset, is a dry-powder formulation of...

October 8, 2019